DelveInsight's“ Alpha-1 Antitrypsin Deficiency Vasculitis Pipeline Insight 2025” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in the Alpha-1 Antitrypsin Deficiency ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted orphan drug designation for KB408 for the treatment of alpha-1 antitrypsin deficiency, according ...

Chronic obstructive pulmonary disease (COPD) is a group of conditions that cause breathing problems. The two main ones are chronic bronchitis and emphysema. Researchers have identified alpha-1 ...

Alpha-1 antitrypsin deficiency, or AATD, is an inherited disease that affects the lung, liver, and skin. The current treatment landscape involves smoking cessation, COPD treatment, and augmentation ...

(RTTNews) - Beam Therapeutics Inc. (BEAM) announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to BEAM-302, a ...

Alpha-1 antitrypsin (AAT) deficiency is a genetic disease where your body doesn’t make enough normal functioning AAT. AAT is a protein your liver makes. AAT has many important roles in your body, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Fazirsiran effectively reduced the ...

Korro Bio, Inc. announced that its investigational drug KRRO-110 has received orphan drug designation from the FDA for treating Alpha-1 Antitrypsin Deficiency (AATD). This designation highlights the ...

NESS ZIONA, Israel--(BUSINESS WIRE)--Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces the completion of enrollment in the ...

Alpha-1 antitrypsin deficiency (AATD) is a hereditary condition characterised by the misfolding of the alpha-1 antitrypsin (AAT) protein, resulting in its hepatic accumulation and compromised protease ...